Shares of Amgen Inc. AMGN inched 0.08% higher to $278.32 Tuesday, on what proved to be an all-around mixed trading session ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Investors recently learned about undisclosed data from one of Amgen's clinical trials. The new information didn't look ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Dragged down by negative returns for shares of Amgen and Nike, the Dow Jones Industrial Average is down Monday morning.

As Amgen (NASDAQ:AMGN) shares are down 9% following the release of highly anticipated phase 2 data on its weight loss drug ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...